These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18638000)

  • 21. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
    Landau D; Tsakok T; Aylwin S; Hughes S
    Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
    J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould DC; Kirby RS
    Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels.
    Zhang X; Zhong Y; Saad F; Haider KS; Haider A; Clendenin AG; Xu X
    Aging Male; 2020 Jun; 23(2):112-118. PubMed ID: 30857458
    [No Abstract]   [Full Text] [Related]  

  • 28. Testosterone and the prostate: implications for the treatment of hypogonadal men.
    Holyoak JD; Crawford ED; Meacham RB
    Curr Urol Rep; 2008 Nov; 9(6):500-5. PubMed ID: 18947516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.
    Asanad K; Horns JJ; Driggs N; Samplaski MK; Hotaling JM
    Int J Impot Res; 2024 Sep; 36(6):655-658. PubMed ID: 38177194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate Risk and Monitoring During Testosterone Replacement Therapy.
    Bhasin S; Thompson IM
    J Clin Endocrinol Metab; 2024 Jul; 109(8):1975-1983. PubMed ID: 38753865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone and prostate cancer: what are the risks for middle-aged men?
    Morgentaler A
    Urol Clin North Am; 2011 May; 38(2):119-24. PubMed ID: 21621078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
    Lenfant L; Leon P; Cancel-Tassin G; Audouin M; Staerman F; Rouprêt M; Cussenot O
    Urol Oncol; 2020 Aug; 38(8):661-670. PubMed ID: 32409202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era of testosterone and prostate cancer: from physiology to clinical implications.
    Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
    Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
    Heaton JP
    Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.